CCNU (NSC 70937): Experience and review

    loading  Checking for direct PDF access through Ovid


A STUDY OF CCNU, used as a single agent or in combination with other agents, was performed in selected tumor types. CCNU was administered by mouth every 6 weeks as a single agent (130 mg/m2 or in combination (90 mg/m2) with other marrow toxic drugs. Nausea and vomiting were the most common side effects. Thrombocytopenia and leukopenia were also commonly seen appearing as delayed, often prolonged, side effects. Sixty-eight patients were treated in this series. Favorable responses were observed in four of four patients with Hodgkin's disease (combined with vinblastine and prednisone), seven of 12 non-Hodgkin's lymphoma (combined with vincristine and prednisone), three of 13 patients with malignant melanoma, one of three with carcinoma of the stomach, and one of 15 with carcinoma of the lung.

    loading  Loading Related Articles